IMMUTEP LIMITED — Director's Dealing 2007

Aug 15, 2007

==> picture [193 x 47] intentionally omitted <==

COMPANY ANNOUNCEMENT

Notice of Clarification to Appendix 3Y

16 August, 2007.

Executive Chairman and acting CEO of Prima Biomed Limited, Mr. Eugene Kopp, wishes to clarify the Appendix 3Y notification concerning his indirect shareholding in the company lodged with the ASX on 15 August 2007.

Mr Kopp still indirectly holds 178,125 shares and 1,000,000 options in the Company.

Further, Mr Kopp received no consideration for the sell down by Bluscan Pty Ltd.

Mr Kopp was the original investment adviser to Bluscan prior to his appointment as Executive Chairman of Prima. However, it was Bluscan investors, not Mr Kopp, who decided to sell their holding in Prima.

Mr. Kopp holds no interest in shares in Bluscan Pty. Ltd.

Clarifying Appendix 3Y is attached.

For further information: Company enquiries

Eugene Kopp

+613 9854 5700

About Prima Biomed Ltd

Prima Biomed (ASX: PRR) is a biotechnology company based in Melbourne, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima’s lead product, CVac™ has completed Phase IIa clinical development in Ovarian Cancer.

For further information, visit www.primabiomed.com.au

Prima BioMed Ltd , Suite 1, 1233 High St, Armadale VIC 3143 AUSTRALIA Ph: +61 (0)3 9854 5700 Fax: +61 (0)3 9822 7735 www.primabiomed.com.au

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of Entity: PRIMA BIOMED LIMITED (ASX:PRR) ABN: 90 009 237 889

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director: Eugene Kopp Date of Last Notice: 21[st] February 2007

Part 1 - Change of Director’s Relevant Interests in Securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or Indirect Interest	Indirect	Indirect	Indirect	Indirect	Indirect
Nature of Indirect Interest (including registered Holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Director related entities: Eugene Kopp is the Managing Director of Bluscan Pty. Ltd. Eugene Kopp is a beneficiary of Pebor Nominees S/F.
Date of Change		(a) 14thAugust 2007 (b) 15thAugust 2007
No. of Securities Held Prior to Change				Options - 1,000,000
			Shares	Options
		Direct	-	-
		Indirect	16,697,495	1,000,000
Class	Shares
Number Acquired				Options - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
Number Disposed			Shares	Options
		Direct	-	-
		Indirect	(a) 14,494,034 (b) 2,025,336 Total 16,519,370	-

• See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		(a) $940,825 (b) $123,545 Total $1,064,370 Of which $961,792 was received by Bluscan Pty Ltd and $102,578 was received by Pebor Nominees S/F.	(a) $940,825 (b) $123,545 Total $1,064,370 Of which $961,792 was received by Bluscan Pty Ltd and $102,578 was received by Pebor Nominees S/F.	(a) $940,825 (b) $123,545 Total $1,064,370 Of which $961,792 was received by Bluscan Pty Ltd and $102,578 was received by Pebor Nominees S/F.
No. of Securities Held After Change				Options - 1,000,000
			Shares	Options
		Direct	-	-
		Indirect	178,125	1,000,000
Nature of Change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-Market Disposal

Part 2 – Change of Director’s Interests in Contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of Contract Nature of Interest Name of Registered Holder (If Issued Securities) Date of Change No. and Class of Securities to Which Interest Related Prior to Change Note: Details are only required for a contract in relation to which the interest has changed Interest Acquired Interest Disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest After Change

==> picture [24 x 15] intentionally omitted <==

www.thecfo.com.au

16.08.2007

• See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002